山西振东制药股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 山西振东制药股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日召开的第六届董事会第六次会议，审议通过了《关于为全资 子公司提供担保的议案》。 因经营发展需要，公司同意为全资子公司山西振东安欣生物制药 有限公司（以下简称"安欣制药"）申请银行授信提供不超过人民币 5,000 万元的担保，担保期限以最终与银行签署的担保协议为准，担 保的形式包括但不限于信用担保（含一般保证、连带责任保证等）、 抵押担保、质押担保或多种担保方式相结合等形式。具体内容详见公 司于 2025 年 10 月 10 日在巨潮资讯网披露的《关于为全资子公司提 供担保的公告》（公告编号 2025-057）。 证券代码：300158 证券简称：振东制药 公告编号：2025-058 二、担保进展情况 近日，公司与中国民生银行股份有限公司太原分行签订了《最高 额保证合同》（以下简称"保证合同"），由公司为全资子公司安欣 制药与中国民生银行股份有限公司太原分行 ...

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]

Market Overview - The Chinese traditional medicine sector rose by 0.84% on October 15, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Zhendong Pharmaceutical (300158) closed at 6.93, with a gain of 5.64% and a trading volume of 913,500 shares, amounting to a transaction value of 636 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 19.62, up 5.31%, with a trading volume of 73,800 shares [1] - Zuoli Pharmaceutical (300181) closed at 19.07, increasing by 4.21%, with a trading volume of 283,300 shares [1] - Other notable performers include Zhongsheng Pharmaceutical (002317) and Xintian Pharmaceutical (002873), with gains of 3.99% and 3.70% respectively [1] Capital Flow - The traditional medicine sector saw a net inflow of 378 million yuan from institutional investors, while retail investors experienced a net outflow of 276 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors withdrew funds [2] Individual Stock Capital Flow - Zuoli Pharmaceutical (300181) had a net inflow of 76.71 million yuan from institutional investors, while retail investors saw a net outflow of 38.14 million yuan [3] - Zhendong Pharmaceutical (300158) experienced a net inflow of 56.45 million yuan from institutional investors, with retail investors withdrawing 51.44 million yuan [3] - Yunnan Baiyao (000538) had a net inflow of 52.53 million yuan from institutional investors, but retail investors withdrew 56.48 million yuan [3]

Core Viewpoint - The innovative drug concept stocks experienced a significant surge in early trading on October 15, with several companies reaching their daily price limits and notable increases in stock prices [1]. Group 1: Stock Performance - Angli康 reached the daily limit up, indicating strong investor interest [1]. - Guangshengtang saw a rise of over 10%, with a notable increase of 14.41% in its stock price [2]. - Other companies such as Saili Medical, Shutaishen, Rongchang Bio, and Lianhuan Pharmaceutical also experienced substantial gains, contributing to the overall positive trend in the innovative drug sector [1]. Group 2: Notable Stock Increases - Guangshengtang (300436) reported a stock increase of 116.94%, with a rise of 14.41% [2]. - Pinlikang (002940) increased by 41.20%, with a rise of 10.01% [2]. - Saili Medical (603716) saw a 27.12% increase, with an 8.35% rise [2]. - Shutaishen (300204) experienced a 34.77% increase, with a 7.88% rise [2]. - Jimin Health (603222) rose by 10.64%, with a 6.72% increase [2]. - Lianhuan Pharmaceutical (600513) increased by 20.21%, with a 6.37% rise [2]. - Rongchang Bio (688331) saw a 97.06% increase, with a 6.31% rise [2]. - Zhendong Pharmaceutical (300158) increased by 6.95%, with a 5.95% rise [2]. - Kangchen Pharmaceutical (035500) rose by 48.68%, with a 4.91% increase [2]. - Maiwei Niwu-U (688062) saw a 46.58% increase, with a 4.86% rise [2].

Core Viewpoint - Zhendong Pharmaceutical announced that neither the company nor its subsidiaries have overdue guarantees, are involved in any litigation related to guarantees, or have incurred losses due to being ruled against in guarantee-related cases [2] Summary by Categories - **Company Status** - Zhendong Pharmaceutical confirmed the absence of overdue guarantees [2] - The company and its subsidiaries are not involved in any litigation concerning guarantees [2] - There are no losses incurred from being ruled against in guarantee-related cases [2]

Group 1 - The core point of the article is that Zhendong Pharmaceutical announced a board meeting to discuss providing guarantees for its wholly-owned subsidiary [1] - For the first half of 2025, Zhendong Pharmaceutical's revenue composition includes: pharmaceutical production and sales accounting for 110.27%, medicinal herb planting at 31.67%, and technical services at 3.38%, with inter-segment eliminations at -45.32% [1] - As of the report, Zhendong Pharmaceutical has a market capitalization of 6.9 billion yuan [1]

证券代码：300158 证券简称：振东制药 公告编号：2025-056 山西振东制药股份有限公司（以下简称"公司"）第六届董事会第 六次会议于 2025 年 10 月 10 日上午 9:00 以通讯表决方式召开，会议 通知于 2025 年 10 月 8 日以电话、邮件等方式通知全体董事（经全体 董事一致同意，豁免本次会议通知的时间要求）。会议应出席董事 9 名，实际出席董事 9 名。会议由公司董事长李昆先生主持，公司部分 高级管理人员列席了会议。本次会议的出席人数、召集、召开程序和 议事内容均符合国家有关法律、法规及《公司章程》的规定。 二、董事会会议审议情况 1、会议以 9 票同意、0 票反对、0 票弃权，审议通过了《关于为 全资子公司提供担保的议案》。 因经营发展需要，公司全资子公司山西振东安欣生物制药有限公 司（以下简称"安欣制药"）拟向银行申请综合授信额度不超过人民币 5,000 万元，授信期限以最终与银行签署的授信协议为准。基于上述 情况，公司拟为安欣制药申请银行授信提供不超过人民币 5,000 万元 的担保，担保期限以最终与银行签署的担保协议为准，担保的形式包 括但不限于信用担保（含一般保证、连带 ...

关于为全资子公司提供担保的公告 证券代码：300158 证券简称：振东制药 公告编号：2025-057 山西振东制药股份有限公司 1、成立日期：1992 年 6 月 12 日 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"）于 2025 年 10 月 10 日召开的第六届董事会第六次会议，审议通过了《关于为全资 子公司提供担保的议案》。现将具体情况公告如下： 一、担保情况概述 因经营发展需要，公司全资子公司山西振东安欣生物制药有限公 司（以下简称"安欣制药"）拟向银行申请综合授信额度不超过人民币 5,000 万元，授信期限以最终与银行签署的授信协议为准。 基于上述情况，公司拟为安欣制药申请银行授信提供不超过人民 币 5,000 万元的担保，担保期限以最终与银行签署的担保协议为准， 担保的形式包括但不限于信用担保（含一般保证、连带责任保证等）、 抵押担保、质押担保或多种担保方式相结合等形式。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司 章程 ...

Core Insights - The traditional Chinese medicine sector saw a rise of 0.96% on October 10, with Wanbangde leading the gains. In contrast, the Shanghai Composite Index fell by 0.94% and the Shenzhen Component Index dropped by 2.7% [1] Group 1: Market Performance - The closing price of Wanbangde was 13.43, with a significant increase of 9.99% and a trading volume of 268,400 shares, amounting to a transaction value of 347 million yuan [1] - Other notable performers included Tianmu Pharmaceutical, which closed at 19.15 with a 4.36% increase, and ST Xiangxue, which rose by 4.32% to close at 10.86 [1] - The overall trading volume for the traditional Chinese medicine sector was substantial, with individual stocks showing varied performance in terms of price changes and trading volumes [1] Group 2: Capital Flow - The traditional Chinese medicine sector experienced a net inflow of 212 million yuan from institutional investors, while retail investors saw a net outflow of 153 million yuan [2] - The capital flow data indicates that while some stocks attracted institutional investment, others faced significant selling pressure from retail investors [3] - Wanbangde had a net outflow of 64.05 million yuan from institutional investors, despite its price increase, indicating a complex market sentiment [3]

Core Viewpoint - Zhen Dong Pharmaceutical (300158.SZ) announced a share buyback program, repurchasing a total of 13,016,700 shares, which represents 1.29% of the company's total share capital, with a total expenditure of RMB 52,030,929 [1] Summary by Relevant Categories Share Buyback Details - The company has repurchased shares through a dedicated securities account via centralized bidding [1] - The highest transaction price for the repurchased shares was RMB 10.06 per share, while the lowest was RMB 3.51 per share [1] - The total amount spent on the buyback, excluding transaction fees, was RMB 52,030,929 [1] Compliance and Regulations - The buyback is in accordance with relevant laws and regulations, as well as the company's share repurchase plan [1]